Allergology International最新文献

{"title":"Corrigendum to \"Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial\" [Allergol Int 74 (2025) 274-82].","authors":"Katsunori Masaki, Maho Suzukawa, Hitoshi Sasano, Norihiro Harada, Yasunari Miyazaki, Hideki Katsura, Etsuko Tagaya, Junko Terada, Masayuki Hojo, Naoya Sugimoto, Hiroyuki Nagase, Yuta Kono, Hisato Hiranuma, Yasuhiro Gon, Ryo Takemura, Misato Irie, Reina Nakamura, Hiroki Kabata, Jun Miyata, Koichi Fukunaga","doi":"10.1016/j.alit.2025.05.001","DOIUrl":"https://doi.org/10.1016/j.alit.2025.05.001","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with egg aversion after a negative oral food challenge result in children with egg allergies: A multicenter questionnaire survey in Japan.","authors":"Naoko Fusayasu, Tomoyuki Asaumi, Ken-Ichi Nagakura, Kyohei Takahashi, Noriyuki Yanagida, Sakura Sato, Shigehito Emura, Akiko Murano, Hisashi Konno, Yasuko Shibukawa, Makoto Suzuki, Motohiro Ebisawa","doi":"10.1016/j.alit.2025.05.005","DOIUrl":"https://doi.org/10.1016/j.alit.2025.05.005","url":null,"abstract":"<p><strong>Background: </strong>Many children with egg allergies experience aversion, which hinders reintroduction after a negative oral food challenge (OFC). We aimed to assess factors associated with egg aversion in children after negative egg OFCs.</p><p><strong>Methods: </strong>We conducted a multicenter questionnaire survey between January and December 2018 and retrospectively collected background data from the medical records. Children aged 3-18 years with a history of an immediate reaction to eggs more than 6 months after a negative OFC to half of a heated whole egg were included. We defined \"aversion\" as a dislike of eating eggs or processed egg products.</p><p><strong>Results: </strong>We included 140 children (median age: 6.7 years) who passed OFCs at the median age of 3.3 years and had a median specific-IgE (sIgE) to egg white of 10.0 kU_A/L. Overall, 57 (41 %) children had an egg aversion. \"Disliking the food texture or taste\" (61 %) was the most frequent reason for an aversion. The associated factor in the multivariate analysis was older age during a negative OFC (adjusted odds ratio: 1.24, 95 % confidence interval: 1.04-1.49). The aversion frequency depended on the type of cooking methods, where 68 % had an aversion to boiled egg whites, and less than 5 % had an aversion to egg-containing deep-fried chicken.</p><p><strong>Conclusions: </strong>About half of the children after negative OFC had an egg aversion, and it was associated with older age during negative OFC. Careful follow-up and guidance with consideration of less aversive cooking methods are important in older age groups.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.","authors":"Yuko Watanabe, Natsumi Hama","doi":"10.1016/j.alit.2025.05.008","DOIUrl":"https://doi.org/10.1016/j.alit.2025.05.008","url":null,"abstract":"<p><p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious mucocutaneous disorders primarily caused by medications. Despite their low incidence, both conditions remain associated with high mortality and significant long-term complications. Recent studies have advanced the understanding of their pathogenesis, including the roles of neutrophil extracellular traps and several cell death pathways. However, reliable biomarkers for early diagnosis are lacking, and no internationally standardized diagnostic criteria have been established. To address these gaps, new diagnostic frameworks have been proposed that incorporate conventional cutaneous and mucosal findings with mandatory histopathological confirmation. These are expected to enhance diagnostic precision and facilitate global comparability. The increasing incidence of SJS/TEN-like reactions associated with immune checkpoint inhibitors and molecular targeted therapies further highlights the importance of accurate histopathological differentiation. Prognostic tools are essential for therapeutic planning. Although the Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) score remains widely used, newer systems offer improved risk stratification and practical utility in diverse clinical settings. However, the optimal use of immunomodulatory therapies remains uncertain owing to limited consensus and evidence. Corticosteroids continue to serve as first-line treatment, but more selective agents are gaining attention for their potential efficacy and reduced toxicity. This review summarizes recent progress in SJS/TEN diagnosis, severity assessment, and management. It discusses the utility and limitations of novel scoring systems and emerging therapies while highlighting persistent challenges, including high mortality, regional practice variation, and delayed standardization. International collaboration and high-quality evidence generation remain essential for improving patient outcomes.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates on the ocular manifestations and treatment of SJS/TEN.","authors":"Chie Sotozono, Mayumi Ueta","doi":"10.1016/j.alit.2025.05.003","DOIUrl":"https://doi.org/10.1016/j.alit.2025.05.003","url":null,"abstract":"<p><p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute inflammatory disorders that affect the skin and mucous membranes, and in 40-84 % of SJS/TEN cases, the ocular complications that are often overlooked due to severe systemic symptoms. Specific ocular findings at the acute-phase include conjunctival hyperemia, pseudomembrane formation, and epithelial defects, and severe acute-phase ocular involvement strongly correlates with long-term visual impairment. Thus, it is vital to diagnose ocular involvement early at the acute stage and suppress inflammation on the ocular surface to protect corneal epithelial stem cells. As outlined in the official Japanese treatment guidelines for SJS/TEN cases with ocular involvement, corticosteroid pulse therapy and topical application of 0.1 % betamethasone eye-drops within four days of disease onset significantly reduces ocular sequelae. Early intervention with amniotic membrane transplantation helps reduce scarring and potential loss of vision. As for genetic-related factors, NSAIDs (nonsteroidal anti-inflammatory drugs) and cold medications are major triggers for SJS/TEN with severe ocular complications, with genetic predispositions involving TLR3 and prostaglandin E receptor 3 (subtype EP3) contributing to disease susceptibility. These genetic-environment interactions influence disease onset and progression. At chronic phase, severe dry eye and visual impairment are major long-term sequelae, and both surgical and non-surgical interventions have been applied to obtain favorable long-term treatment outcomes. In summary, early ophthalmic intervention is critical in preventing SJS/TEN-related ocular sequelae, and further research into genetic and immunological mechanisms is essential for better diagnosis and treatment.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YTHDF1 regulates the proliferation and differentiation of keratinocytes via the PI3K/AKT signaling pathway in atopic dermatitis.","authors":"Maoxin Huang, Liping Dong, Yue He, Xinying Cai, Yun Lu, Jinlei Xu, Fengli Xiao","doi":"10.1016/j.alit.2025.04.005","DOIUrl":"https://doi.org/10.1016/j.alit.2025.04.005","url":null,"abstract":"<p><strong>Background: </strong>YTHDF1, a critical regulator of cellular processes, has attracted attention for its involvement in some inflammatory diseases. However, its specific association with atopic dermatitis (AD) remains unclear. The objective is to investigate the functional roles and underlying mechanisms of YTHDF1 in AD.</p><p><strong>Methods: </strong>The expression of YTHDF1 was investigated by bioinformatics analysis and skin lesions of AD patients. The functional role and upstream and downstream regulatory mechanisms of YTHDF1 were examined through a series of in vitro and in vivo experiments. Adeno-associated virus (AAV)-mediated delivery of YTHDF1 in the AD mouse model was evaluated for its therapeutic potential.</p><p><strong>Results: </strong>Bioinformatics analysis revealed that the YTHDF1 mRNA level in the skin lesions of AD was significantly higher than that in healthy people. YTHDF1 expression was significantly elevated in AD skin lesions, the DNCB-induced AD mouse model, and primary human keratinocytes and HaCaT cells stimulated with interleukin (IL)-4/IL-13, compared to controls. Both in vitro and in vivo experiments revealed that upregulation of YTHDF1 in AD exacerbated cell proliferation and inhibited keratinization by activating the PI3K/AKT pathway, which was modulated via the IL-4/IL-13/STAT3 axis. Moreover, topical application of AAV-YTHDF1 significantly improved AD-like lesions in the mouse model.</p><p><strong>Conclusions: </strong>This study identifies YTHDF1 as a contributor to AD pathogenesis by influencing keratinocyte proliferation and differentiation. It also suggests that YTHDF1 could be a potential therapeutic target for AD treatment.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of YKL-40 for understanding pathophysiology of obstructive airway disorders.","authors":"Yasuhito Suzuki, Junpei Saito, Masami Kikuchi, Suguru Sato, Atsuro Fukuhara, Mami Rikimaru, Hikaru Tomita, Kentaro Kazama, Koshi Saito, Rina Harigane, Riko Sato, Ryuki Yamada, Natsumi Watanabe, Takashi Umeda, Ryuichi Togawa, Yuki Sato, Hiroyuki Minemura, Takefumi Nikaido, Kenya Kanazawa, Xintao Wang, Yoshinori Tanino, Yoko Shibata","doi":"10.1016/j.alit.2025.05.004","DOIUrl":"https://doi.org/10.1016/j.alit.2025.05.004","url":null,"abstract":"<p><strong>Background: </strong>Chitinase-3-like protein 1 (YKL-40) has been reported as a biomarker of neutrophilic airway inflammation in obstructive airway disorders. However, the pathophysiological features of YKL-40 remain unclear. The aim of the study is to evaluate the associations between YKL-40 and clinical features in patients with asthma, chronic obstructive pulmonary disease (COPD), or asthma-COPD overlap (ACO).</p><p><strong>Methods: </strong>Serum and sputum YKL-40 levels were measured in 46 asthmatics, 35 COPD, and 32 ACO patients.</p><p><strong>Results: </strong>Serum YKL-40 levels were elevated in the COPD and ACO patients, and sputum YKL-40 levels were higher in the COPD patients compared to the asthmatics. Both serum and sputum YKL-40 levels positively correlated with sputum neutrophils. Only serum YKL-40 levels negatively correlated with FEV₁ (%predicted), FEV₁/FVC, and annual decline in FEV₁. In 15 patients whose paired serum samples were obtained within 6 months, changes in serum YKL-40 levels showed a significant positive correlation with those in FEV₁. Furthermore, patients who had experienced exacerbations either in the past year or the following year showed significantly greater serum, but not sputum, YKL-40 levels. Sputum YKL-40 levels showed significant correlations with scores on the COPD assessment test and modified Medical Research Council dyspnea scale.</p><p><strong>Conclusions: </strong>Serum and sputum YKL-40 may reflect distinct clinical features in obstructive airway disorders. Serum YKL-40 may provide beneficial information on predicting obstructive neutrophilic inflammation and exacerbations, whilst sputum YKL-40 may offer valuable insights for evaluating ongoing symptoms. Concomitant measurement of YKL-40 in serum and sputum might be more useful than individual measurement.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates in the pathogenesis of SJS/TEN.","authors":"Joy Justice, Eric Mukherjee, Michelle Martin-Pozo, Elizabeth Phillips","doi":"10.1016/j.alit.2025.05.002","DOIUrl":"https://doi.org/10.1016/j.alit.2025.05.002","url":null,"abstract":"<p><p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions across a spectrum of severity characterized by widespread epidermal detachment and keratinocyte apoptosis. SJS/TEN develops due to a complex immunologic response after exposure to an associated drug antigen and/or its metabolite, and it results in significant morbidity and mortality. Complex immune mechanisms contribute to keratinocyte death. Drug-induced SJS/TEN has been shown to be strongly HLA class I restricted which has contributed to our understanding of mechanisms and has the potential to shape prevention and diagnosis. There is currently no evidence-based treatment outside of aggressive supportive care, and understanding the complete immunopathogenesis of SJS/TEN will be key for the development of efficacious and safe treatments that significantly reduce morbidity and mortality. This article focuses on what is new in the pathogenesis of SJS/TEN, including recent research on the mechanisms of T-cell activation, apoptotic and necroptotic mediators, other related molecules, genetic associations, and possible targeted treatment options.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of GATA2 in the expression of the soluble decoy receptor ST2/IL1RL1 in human and mouse mast cells.","authors":"Kazuki Nagata, Kazumi Kasakura, Kenta Ishii, Naoto Ito, Mutsuko Hara, Nobuhiro Nakano, Ko Okumura, Chiharu Nishiyama","doi":"10.1016/j.alit.2025.04.004","DOIUrl":"https://doi.org/10.1016/j.alit.2025.04.004","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144133345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exacerbated signs of atopic dermatitis with gut dysbiosis predominate in male than in female adult patients.","authors":"Susumu Ichiyama, Kozo Ohkusu-Tsukada, Hidehisa Saeki","doi":"10.1016/j.alit.2025.04.002","DOIUrl":"https://doi.org/10.1016/j.alit.2025.04.002","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophils predominate as IL1B-expressing cells in Schnitzler syndrome: Insights from the SCan study to evaluate the efficacy and safety of canakinumab in Japanese patients.","authors":"Naotomo Kambe, Norimitsu Inoue, Yoko Ueki, Yuyi Zhou, Satoru Yonekura, Kosuke Katsuo, Satoshi Nakamizo, Hiroshi Tsujimoto, Katsuki Ohtani, Hajime Yoshifuji, Tomoyasu Jo, Kazushi Izawa, Mayuko Yamamoto, Koji Takemura, Shin-Ichiro Kagami, Yoshie Kawahara, Yoko Amino, Yumiko Ibi, Satoshi Morita, Nobuo Kanazawa","doi":"10.1016/j.alit.2025.04.003","DOIUrl":"https://doi.org/10.1016/j.alit.2025.04.003","url":null,"abstract":"<p><strong>Background: </strong>Schnitzler syndrome (SchS) is a late-onset autoinflammatory disease characterized by urticarial rash and monoclonal gammopathy. SchS shares clinical features with cryopyrin-associated periodic syndrome, which is driven by gain-of-function mutations in NLRP3, and while IL-1β-targeted therapies have shown efficacy, the underlying pathogenesis of SchS remains unclear.</p><p><strong>Methods: </strong>During a multicenter, single-arm, open-label, investigator-initiated trial evaluating the efficacy and safety of canakinumab in five Japanese patients with SchS (named the SCan Study after SchS and Canakinumab), based on a similar study conducted in Germany, we measured 32 cytokines/chemokines and 11 complement-related factors in plasma and analyzed their correlations with changes in clinical symptoms during treatment. Furthermore, in two cases, single-cell RNA sequencing of peripheral blood and spatial transcriptomic analysis of lesional skin were performed to identify IL1B-expressing cells.</p><p><strong>Results: </strong>The improvement in clinical symptoms and quality of life was maintained for 48 weeks following canakinumab treatment. Notably, these changes in clinical symptoms strongly correlated with WBC count, neutrophil count, CRP, and serum amyloid A levels, which were used as evaluation parameters in this study. In contrast, IL-1β and most other cytokines/chemokines exhibited distinct patterns and were not useful as markers of disease activity. IgM levels remained stable without an upward trend. Additionally, IL1B-expressing cells were predominantly neutrophils in both peripheral blood and lesional skin. Furthermore, neutrophil counts in peripheral blood decreased following canakinumab administration.</p><p><strong>Conclusions: </strong>This study demonstrated that the primary source of IL1B-expressing cells in SchS is neutrophils. Moreover, canakinumab improves clinical symptoms by regulating neutrophil dynamics in peripheral blood.</p>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}